{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:22:46Z","timestamp":1775082166183,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400160"],"award-info":[{"award-number":["81400160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070218"],"award-info":[{"award-number":["82070218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2017J01185"],"award-info":[{"award-number":["2017J01185"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical research project of Wu Jieping Medical Foundation","award":["320.6750.19094-41 and 320.6750.19094-58"],"award-info":[{"award-number":["320.6750.19094-41 and 320.6750.19094-58"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The development of multiple myeloma (MM) is considered to involve a multistep transformation process, but the role of cytogenetic abnormalities and molecular alterations in determining the cell fate of multiple myeloma (MM) remains unclear. Here, we have analyzed single cell RNA-seq data and bulk gene profiles to reveal a novel signature associated with MM development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The scRNA-seq data from GSE118900 was used to profile the transcriptomes of cells from MM patients at different stages. Pseudotemporal ordering of the single cells was performed using Monocle package to feature distinct transcriptomic states of the developing MM cells. The bulk microarray profiles from\u00a0GSE24080 and GSE9782 were applied to identify a signature associated with MM development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 597 cells were divided into 7 clusters according to different risk levels. They were initiated mainly from monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed MM (NDMM), or relapsed and\/or refractory myeloma (RRMM) with cytogenetically favorable t(11;14), moved towards the cells from smoldering MM (SMM) or NDMM without t(11;14) or t(4;14), and then finally to cells from SMM or RRMM with t(4;14). Based on the markers identified in the late stage, the bulk data was used to develop a 20-gene signature stratifying patients into high and low-risk groups (GSE24080: HR\u2009=\u20093.759, 95% CI 2.746\u20135.145; GSE9782: HR\u2009=\u20092.612, 95% CI 1.894\u20133.603), which was better than the previously published gene signatures (EMC92, UAMS70, and UAMS17) and International Staging System. This signature also succeeded in predicting the clinical outcome of patients treated with bortezomib (HR\u2009=\u20092.884, 95% CI 1.994\u20134.172, <jats:italic>P<\/jats:italic>\u2009=\u20091.89e\u22128). The 20 genes were further verified by quantitative real-time polymerase chain reaction using samples obtained from the patients with MM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our comprehensive analyses offered new insights in MM development, and established a 20-gene signature as an independent biomarker for MM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02190-6","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T19:02:53Z","timestamp":1632596573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhiyong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizhe","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-1677","authenticated-orcid":false,"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"11","key":"2190_CR1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"2190_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101\u201319.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2190_CR3","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3324\/haematol.2018.211110","volume":"104","author":"VG Ramakrishnan","year":"2019","unstructured":"Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, et al. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. Haematologica. 2019;104(10):2061\u201374.","journal-title":"Haematologica"},{"issue":"15","key":"2190_CR4","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2190_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28(2):384\u201390.","journal-title":"Leukemia"},{"issue":"1","key":"2190_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","volume":"9","author":"JS Jang","year":"2019","unstructured":"Jang JS, Li Y, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, et al. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J. 2019;9(1):2.","journal-title":"Blood Cancer J"},{"issue":"8","key":"2190_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1101\/gr.228080.117","volume":"28","author":"J Fan","year":"2018","unstructured":"Fan J, Lee HO, Lee S, Ryu DE, Lee S, Xue C, et al. Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Res. 2018;28(8):1217\u201327.","journal-title":"Genome Res"},{"issue":"12","key":"2190_CR8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24(12):1867\u201376.","journal-title":"Nat Med"},{"issue":"5","key":"2190_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","volume":"161","author":"EZ Macosko","year":"2015","unstructured":"Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161(5):1202\u201314.","journal-title":"Cell"},{"issue":"10","key":"2190_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14(10):979\u201382.","journal-title":"Nat Methods"},{"issue":"5","key":"2190_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"17","key":"2190_CR12","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/bioinformatics\/btv300","volume":"31","author":"W Walter","year":"2015","unstructured":"Walter W, Sanchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912\u20134.","journal-title":"Bioinformatics"},{"issue":"1","key":"2190_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1\u201322.","journal-title":"J Stat Softw"},{"issue":"10","key":"2190_CR14","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557\u201360.","journal-title":"Blood"},{"issue":"20","key":"2190_CR15","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043\u201351.","journal-title":"Blood"},{"issue":"6","key":"2190_CR16","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276\u201384.","journal-title":"Blood"},{"issue":"11","key":"2190_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406\u201313.","journal-title":"Leukemia"},{"issue":"2","key":"2190_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/bjh.16744","volume":"192","author":"M Zamani-Ahmadmahmudi","year":"2021","unstructured":"Zamani-Ahmadmahmudi M, Nassiri SM, Soltaninezhad F. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma. Br J Haematol. 2021;192(2):310\u201321.","journal-title":"Br J Haematol"},{"issue":"43","key":"2190_CR19","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"2190_CR20","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008;26(29):4798\u2013805.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2190_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"key":"2190_CR22","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.","journal-title":"Nat Commun"},{"issue":"1","key":"2190_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood.V91.1.3","volume":"91","author":"M Hallek","year":"1998","unstructured":"Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):3\u201321.","journal-title":"Blood"},{"issue":"1","key":"2190_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101.","journal-title":"Cancer Cell"},{"issue":"5","key":"2190_CR25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","volume":"120","author":"BA Walker","year":"2012","unstructured":"Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120(5):1077\u201386.","journal-title":"Blood"},{"issue":"4","key":"2190_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.12805","volume":"165","author":"A Brioli","year":"2014","unstructured":"Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014;165(4):441\u201354.","journal-title":"Br J Haematol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02190-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02190-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02190-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T19:13:00Z","timestamp":1632597180000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02190-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02190-6","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the First Affiliated Hospital of Fujian Medical University approved the collection of the patient samples, the isolation of tumor cells, and the analysis of the obtained samples. All procedures of samples acquirements have followed the tenets of the Declaration of Helsinki. The informed consents were obtained from all individual patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"511"}}